



CHIEF NATIONAL GUARD BUREAU INSTRUCTION

NG-J39
DISTRIBUTION: A

CNGBI 3502.01
Issued 14 May 2014
Expired 14 May 2019
Validity Extended to 14 May 2022

NATIONAL GUARD CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR RESPONSE ENTERPRISE SMALLPOX AND ANTHRAX VACCINE IMMUNIZATION PROGRAMS

References: See Enclosure A.

1. Purpose. The purpose of this instruction is to implement the policies outlined in references a and b and to establish the National Guard (NG) Combating Weapons of Mass Destruction Division (NG-J39) as the office that designates National Guardsmen, assigned by unit or position, to the NG Chemical, Biological, Radiological, and Nuclear (CBRN) Response Enterprise.
2. Cancellation. None.
3. Applicability. This instruction applies to all States, Territories, and the District of Columbia, hereafter referred to as "States."
4. Policy. States will implement a smallpox vaccination program (SVP) and an anthrax vaccination immunization program (AVIP) for all of their NG personnel assigned to the NG CBRN Response Enterprise (CRE). Everyone assigned to the NG CRE must comply. The Adjutants General enforce this policy; their subordinate commanders implement it. Units or personnel scheduled to rotate off the NG CRE within 180 days of the date of this policy are administratively exempt from starting the subject vaccinations. Clinical and administrative policies for SVPs and AVIPs, including exception policies and references c through m, apply as well as all other laws, regulations, and policies related to the two immunization programs. Service members both permanently and medically exempt from SVP or AVIP immunizations may be retained in the NG CRE. Service members not otherwise exempt, yet refusing to comply with the terms of this guidance may be removed from the NG CRE.

UNCLASSIFIED

5. Definitions. See Glossary.

6. Responsibilities.

a. NG-J39 is the office of primary responsibility (OPR) for tracking the NG CRE's readiness status. NG-J39 establishes policies and procedures for reporting the States' NG CRE readiness.

b. States are responsible for assigning National Guardsmen by unit and position to their respective NG CRE units and reporting these assignments in accordance with (IAW) the NG-J39 policies and procedures.

c. States are responsible for securing the smallpox and anthrax vaccines and developing supporting vaccination programs for their respective NG CRE units. States will comply with clinical policies and vaccination reporting requirements IAW references k, l, and m.

d. In addition to following the adverse reporting requirements outlined in references k, l, and m, States will report serious adverse reactions or accidental inoculations within 24 hours to the National Guard Bureau (NGB) Joint Surgeon's Office by calling the NG Coordination Center Team Chief. Reports must include a State point of contact and exclude personally identifiable information.

7. Summary of Changes. This is the initial publication of CNGBI 3502.01.

8. Releasability. This instruction is approved for public release; distribution is unlimited. NGB directorates, The Adjutants General, the Commanding General of the District of Columbia, and Joint Force Headquarters-State may obtain copies of this instruction through <<http://www.ngbpd.cngbi.army.mil>>.

9. Effective Date. This instruction is effective upon publication and must be reissued, cancelled, or certified as current within five years of its publication.


FRANK J. GRASS
General, USA
Chief, National Guard Bureau

Enclosures:

A -- References
GL -- Glossary

ENCLOSURE A

REFERENCES

- a. DepSec Memorandum, 18 November 2012, “Smallpox and Anthrax Vaccine Immunization Programs for the U.S. Northern Command Chemical, Biological, Radiological, and Nuclear Response Enterprise”
- b. DepSec Memorandum, 03 March 2014, “Additional Policy Guidance for Smallpox and Anthrax Vaccine Immunization Programs for the U.S. Northern Command Chemical, Biological, Radiological, and Nuclear Response Enterprise”
- c. DepSec Memorandum, 28 June 2002, “Reintroduction of the Anthrax Vaccine Immunization Program (AVIP)”
- d. USD (P&R) Memorandum, 06 August 2002, “Policy on Administrative Issues Related to the Anthrax Vaccine Immunization Program (AVIP)”
- e. DepSec Memorandum, 30 September 2002, “Department of Defense Smallpox Response Plan”
- f. USD (P&R) Memorandum, 13 December 2002, “Policy on Administrative Issues Related to Smallpox Vaccination Program (SVP)”
- g. DepSec Memorandum, 28 June 2004, “Expansion of Force Health Protection Anthrax and Smallpox Immunization Programs for DoD Personnel”
- h. USD (P&R) Memorandum, 22 September 2004, “Expansion of Force Health Protection Anthrax and Smallpox Immunization Programs for Emergency-Essential and Equivalent Department of Defense Civilian Employees”
- i. USD (P&R) Memorandum, 06 December 2006, “Implementation of the Anthrax Vaccine Immunization Program (AVIP)”
- j. USD (P&R) Memorandum, 10 September 2007, “Change in Policy for Pre-Deployment Administration of Anthrax and Smallpox Vaccines”
- k. Assistant SecDef (HA) Memorandum, 01 April 2008, “Update to Clinical Policy for the Department of Defense Smallpox Vaccination Program”
- l. Assistant SecDef (HA) Memorandum, 31 July 2009, “Clinical Policy for the Administration of the Anthrax Vaccine Adsorbed”

CNGBI 3502.01

14 May 2014

Extended to 14 May 2022

m. AR 40-562, BUMEDINST 6230.15B, AF Instruction 48-110_IP, and CG
COMDTINST M6230.4G, 07 October 2013, “Immunizations and
Chemoprophylaxis for the Prevention of Infectious Diseases”

GLOSSARY

PART I. ABBREVIATIONS AND ACRONYMS

AVIP	Anthrax Vaccine Immunization Program
CBRN	Chemical, Biological, Radiological, and Nuclear
CNGB	Chief National Guard Bureau
CRE	Chemical, Biological, Radiological, and Nuclear Response Enterprise
IAW	In accordance with
NG	National Guard
NGB	National Guard Bureau
NG-J39	National Guard Combating Weapons of Mass Destruction Division
OPR	Office of Primary Responsibility
SVP	Smallpox Vaccination Program

PART II. DEFINITIONS

(NONE)